Melanoma treatment after surgery and its effect on fertility
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at how adjuvant therapy (treatment after surgery) affects fertility in women under 40 who have had their melanoma completely removed. It will help doctors understand and manage the impact on future childbearing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and under 40 years old.
- Your melanoma (stage II, III, or IV) was completely removed by surgery.
- You have not had chemotherapy or radiation therapy before.
- You do not have conditions that could cause early menopause or infertility.
- You are able to give your permission to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how anti-cancer treatment affects a person’s egg reserve (for women) or semen quality (for men) over time. It may help doctors better understand fertility-related side effects of melanoma therapy and how they evolve during routine treatment.
This study looks at fertility, cancer outcomes, and children's health in women diagnosed with breast cancer at age 40 or younger. It aims to help you understand how breast cancer and its treatment may affect your ability to have children and your long-term health.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study tests whether adding metformin to vemurafenib can shrink advanced melanoma in people with a specific gene change (BRAF V600E). It’s an early-phase trial, so the main goal is to see if the combination is safe and whether it may work better than expected.
This study looks at how immune checkpoint inhibitors (a type of immunotherapy) affect fertility and hormone health in premenopausal women and men with melanoma. It aims to understand and manage these side effects while you receive treatment.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.